View ValuationKorro Bio 향후 성장Future 기준 점검 2/6Korro Bio 의 수익은 연간 12.7% 감소할 것으로 예상되는 반면, 연간 수익은 61.7% 로 증가할 것으로 예상됩니다. EPS는 연간 12% 만큼 성장할 것으로 예상됩니다.핵심 정보-12.7%이익 성장률12.01%EPS 성장률Biotechs 이익 성장25.2%매출 성장률61.7%향후 자기자본이익률n/a애널리스트 커버리지Good마지막 업데이트08 May 2026최근 향후 성장 업데이트Major Estimate Revision • May 14Consensus EPS estimates upgraded to US$5.27 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$6.75 to -US$5.27 per share. Revenue forecast unchanged from US$500.0k at last update. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$20.38 unchanged from last update. Share price fell 16% to US$11.20 over the past week.Major Estimate Revision • Mar 19Consensus revenue estimates increase by 52,586%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$1.27m to US$667.4m. Forecast losses expected to reduce from -US$8.27 to -US$6.75 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$19.33 to US$20.00. Share price fell 3.8% to US$11.06 over the past week.Price Target Changed • Feb 12Price target increased by 123% to US$19.33Up from US$8.67, the current price target is an average from 6 analysts. New target price is 64% above last closing price of US$11.76. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$9.05 next year compared to a net loss per share of US$9.37 last year.Price Target Changed • Sep 10Price target decreased by 8.4% to US$92.33Down from US$101, the current price target is an average from 9 analysts. New target price is 156% above last closing price of US$36.12. Stock is down 7.0% over the past year. The company is forecast to post a net loss per share of US$10.14 next year compared to a net loss per share of US$9.37 last year.Major Estimate Revision • Aug 19Consensus revenue estimates increase by 47%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$3.31m to US$4.85m. EPS estimate fell from -US$9.55 to -US$10.14 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$99.23. Share price rose 20% to US$19.14 over the past week.Price Target Changed • May 16Price target decreased by 13% to US$102Down from US$117, the current price target is an average from 10 analysts. New target price is 574% above last closing price of US$15.11. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$9.55 next year compared to a net loss per share of US$9.37 last year.모든 업데이트 보기Recent updatesMajor Estimate Revision • May 14Consensus EPS estimates upgraded to US$5.27 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$6.75 to -US$5.27 per share. Revenue forecast unchanged from US$500.0k at last update. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$20.38 unchanged from last update. Share price fell 16% to US$11.20 over the past week.Reported Earnings • May 07First quarter 2026 earnings released: US$1.69 loss per share (vs US$2.49 loss in 1Q 2025)First quarter 2026 results: US$1.69 loss per share (improved from US$2.49 loss in 1Q 2025). Net loss: US$19.6m (loss narrowed 16% from 1Q 2025). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.공시 • Apr 17Korro Bio, Inc., Annual General Meeting, Jun 10, 2026Korro Bio, Inc., Annual General Meeting, Jun 10, 2026.Major Estimate Revision • Mar 19Consensus revenue estimates increase by 52,586%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$1.27m to US$667.4m. Forecast losses expected to reduce from -US$8.27 to -US$6.75 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$19.33 to US$20.00. Share price fell 3.8% to US$11.06 over the past week.New Risk • Mar 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 9.8% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$108m net loss in 3 years).공시 • Mar 09Korro Bio, Inc. announced that it expects to receive $84.996839 million in funding from a group of investorsKorro Bio, Inc announced a private placement and entered into a subscription agreement to issue 4,501,928 common shares at price of $11.11 per share for aggregate proceeds of $50,016,420.08 and 3,148,836 pre-funded warrants at a price of $11.109 for aggregate proceeds of $34,980,419.124, total gross proceeds amounting to $84,996,839.204 on March 9. 2026. The transaction included participation from lead Investor Venrock Healthcare Capital Partners, ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, and New Enterprise Associates. The pre-funded warrants have an exercise price of $0.001 per underlying share of common stock, are immediately exercisable and have no expiration date. The transaction is expected to close on March 10, 2026 subject to customary closing conditions. The securities will be issued in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the 1933 Act and not in reliance upon any of the safe harbors set forth in Regulation D promulgated thereunder.Price Target Changed • Feb 12Price target increased by 123% to US$19.33Up from US$8.67, the current price target is an average from 6 analysts. New target price is 64% above last closing price of US$11.76. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$9.05 next year compared to a net loss per share of US$9.37 last year.Board Change • Feb 12High number of new and inexperienced directorsThere are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Independent Director Ali Behbahani is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Nov 13+ 2 more updatesKorro Bio, Inc. Provides Updates on KRRO-110 in Alpha-1 Antitrypsin DeficiencyKorro Bio, Inc. provided a program update for its Phase 1/2a REWRITE clinical trial of KRRO-110 in AATD. The REWRITE Phase 1/2a clinical trial is a two-part single and multiple-dose escalating study evaluating the safety and tolerability of KRRO-110, including healthy adults and clinically stable AATD patients with the PiZZ genotype. Korro has completed all six planned single ascending dose (SAD) healthy volunteer (HV) cohorts. Each HV cohort consisted of six participants, with four receiving active drug and two receiving placebo. Doses of KRRO-110 tested in the HVs (n=24) include 0.04, 0.1, 0.2, 0.4, 0.8 and 1.2 mg/kg, with the primary objective to evaluate safety and tolerability. KRRO-110 is currently being evaluated in two AATD patient cohorts at 0.6 mg/kg (n=3) and 0.8 mg/kg (n=4), with seven patients dosed. The AATD patient cohorts are open label with up to four patients in each cohort. There are currently no plans to complete additional SAD patient cohorts for KRRO-110. Korro is evaluating the totality of the clinical data to evaluate the next steps, if any, for KRRO-110 in the multiple-ascending dose (MAD) portion of the REWRITE clinical trial. KRRO-110 Safety Observations (as of the November 6, 2025 Data Cutoff Date): No dose-limiting toxicities or treatment emergent serious adverse events observed. Mild-to-moderate infusion-related reactions (IRRs) observed in two healthy volunteers at the highest dose of 1.2 mg/kg, two AATD patients at 0.6 mg/kg, and two AATD patients at 0.8 mg/kg. All IRRs resolved within 24 hours post KRRO-110 dosing; intervention was limited to antipyretics and antihistamines. KRRO-110 safety profile is consistent with Lipid Nanoparticles (LNP) infusion-related class effects. KRRO-110 Pharmacodynamic and Pharmacokinetic Observations (as of the November 6, 2025 Data Cutoff Date): Across five AATD patients in the two SAD cohorts evaluable with turbidimetry, the greatest peak total AAT protein was approximately 10 µM and the greatest increase of total AAT protein from baseline was approximately 3 µM. The total AAT protein levels following single-dose administration did not reach the protective threshold of 11 µM. In three of the AATD patients dosed with 0.8 mg/kg evaluable with LC/MS, functional M-AAT protein was observed in each of the patients following administration of KRRO-110. The greatest increase of M-AAT protein from baseline observed at any time point was approximately 2 µM. Functional M-AAT protein lasted up to four weeks for the first patient evaluable with LC/MS, consistent with durability of editing and endogenous M-AAT protein half-life. Pharmacokinetic differences in the components of KRRO-110 in plasma were observed between HV and AATD patients, with apparent faster disassociation of KRRO-110, suggesting variability of this formulation in AATD patients compared to HV following a single dose. No evidence of bystander editing observed to date, suggesting high specificity, based on LC/MS data on M-AAT and Z-AAT. KRRO-110 Regulatory Milestones Validate OPERA Platform Potential: First-ever RNA editing technology to receive Investigational New Drug clearance by the U.S. Food and Drug Administration (FDA) to Korro’s knowledge. Fast Track designation granted by the FDA. Orphan Drug Designation granted by both the FDA and European Medicines Agency.분석 기사 • Oct 23Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Oct 08Korro Bio, Inc. Announces Chief Financial Officer Changes, Effective October 17, 2025On October 7, 2025, Vineet Agarwal announced his intention to resign from his position of Chief Financial Officer of Korro Bio, Inc., or Korro, effective October 17, 2025 to pursue another opportunity. In order to ensure the smooth transition of his functions, Mr. Agarwal has agreed to be available to serve as an advisor for 30 days thereafter. The board of directors of Korro, or the Board, and Korro are incredibly thankful to Mr. Agarwal for his long-standing service at Korro. In light of Mr. Agarwal’s resignation, the Board appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim Chief Financial Officer and principal financial officer, in addition to his current duties effective from October 17, 2025.Price Target Changed • Sep 10Price target decreased by 8.4% to US$92.33Down from US$101, the current price target is an average from 9 analysts. New target price is 156% above last closing price of US$36.12. Stock is down 7.0% over the past year. The company is forecast to post a net loss per share of US$10.14 next year compared to a net loss per share of US$9.37 last year.Major Estimate Revision • Aug 19Consensus revenue estimates increase by 47%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$3.31m to US$4.85m. EPS estimate fell from -US$9.55 to -US$10.14 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$99.23. Share price rose 20% to US$19.14 over the past week.분석 기사 • Jul 05We're Keeping An Eye On Korro Bio's (NASDAQ:KRRO) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...공시 • Jun 30+ 5 more updatesKorro Bio, Inc.(NasdaqCM:KRRO) dropped from Russell 3000E Growth IndexKorro Bio, Inc.(NasdaqCM:KRRO) dropped from Russell 3000E Growth IndexNew Risk • Jun 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 9.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years). Revenue is less than US$5m (US$4.8m revenue).Price Target Changed • May 16Price target decreased by 13% to US$102Down from US$117, the current price target is an average from 10 analysts. New target price is 574% above last closing price of US$15.11. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$9.55 next year compared to a net loss per share of US$9.37 last year.Major Estimate Revision • May 14Consensus revenue estimates increase by 137%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from US$1.35m to US$3.20m. Forecast losses expected to reduce from -US$10.23 to -US$9.51 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$117 to US$102. Share price was steady at US$14.11 over the past week.공시 • Apr 30Korro Bio, Inc., Annual General Meeting, Jun 11, 2025Korro Bio, Inc., Annual General Meeting, Jun 11, 2025.Price Target Changed • Apr 29Price target decreased by 7.3% to US$117Down from US$126, the current price target is an average from 10 analysts. New target price is 601% above last closing price of US$16.67. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$10.23 next year compared to a net loss per share of US$9.37 last year.Major Estimate Revision • Apr 24Consensus revenue estimates increase by 156%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$250.0k to US$640.0k. EPS estimate unchanged from -US$10.40 at last update. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$139 to US$122. Share price rose 25% to US$17.44 over the past week.Price Target Changed • Apr 17Price target decreased by 9.9% to US$126Down from US$140, the current price target is an average from 9 analysts. New target price is 807% above last closing price of US$13.90. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$10.40 next year compared to a net loss per share of US$9.37 last year.공시 • Apr 01Korro Bio, Inc. Appoints Loïc Vincent as Chief Scientific OfficerKorro Bio, Inc. announced the appointment of Loïc Vincent as Chief Scientific Officer. Dr. Vincent joins Korro with more than 20 years in drug discovery and translational research across academia, biotech and the pharmaceutical industry. Throughout his career, Dr. Vincent led teams that advanced more than 20 drugs into clinical development based on various therapeutic modalities including small molecules, biologics, viral platforms and cell therapies. Prior to joining Korro, Dr. Vincent served as Chief Scientific Officer at Affini-T Therapeutics leading efforts to advance next-generation therapies. Previously, he was Head of the Oncology Drug Discovery Unit and Immunology Unit at Takeda. Before that, Dr. Vincent led Oncology Drug Discovery Pharmacology, Immunotherapy and Oncology External Innovation teams at Sanofi, and earlier in his career, he headed Pharmacology and Oncology programs at Endotis Pharma. Dr. Vincent currently serves on the Scientific Advisory Boards of bit.bio and General Inception, and is a Director on the Board of Alaya.bio. Dr. Vincent obtained his Ph.D. in pharmacology from the University of Rouen, France, and completed his postdoctoral fellowship in oncology at the Weill Medical College of Cornell University, New York.분석 기사 • Mar 19Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although...공시 • Feb 13Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting OfficerEffective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., is taking a temporary medical leave of absence. Accordingly, effective from February 11, 2025, Korro’s Board of Directors appointed Mr. Oliver Dolan, Senior Vice President, Finance, to serve as Korro’s interim principal accounting officer, in each case, in addition to their current duties. Mr. Dolan, age 42, has served as Korro’s Senior Vice President of Finance since January 2024. Prior to joining Korro, Mr. Dolan served as Vice President, Accounting, Tax and Treasury at Unity Biotechnology from December 2020 to December 2023. Prior to that, Mr. Dolan served as Head of Finance at Haven Healthcare from May 2020 to December 2020. Prior to that, Mr. Dolan served as Vice President of Finance at Compass Therapeutics from October 2018 to May 2020. Mr. Dolan holds an MBA from MIT Sloan School of Management, a Bachelor of Commerce degree from the University College Dublin and he is licensed as a Certified Public Accountant.공시 • Jan 13Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin DeficiencyKorro Bio, Inc. announced the initiation of dosing in its REWRITE study investigating KRRO-110 as a potential treatment for individuals with Alpha-1 Antitrypsin Deficiency (AATD). REWRITE is a two-part single and multiple dose-escalating study that will evaluate the safety and tolerability of KRRO-110 in up to 64 participants, including healthy adults and clinically stable AATD patients with the PiZZ genotype. Secondary and exploratory endpoints include pharmacokinetic and pharmacodynamic parameters that will guide optimal dose selection for later stage studies. Interim data from Part 1 (single ascending doses in healthy volunteers and individuals with AATD) is expected in the second half of 2025, and completion of the study is anticipated in 2026. For additional information about the REWRITE study, visit ClinicalTrials.gov (NCT06677307). In addition to advancing KRRO-110, Korro is progressing a pipeline of wholly owned programs and a Novo Nordisk partnered program in a cardiometabolic indication towards the clinic.공시 • Dec 03Korro Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Korro Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering분석 기사 • Nov 28We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although...Recent Insider Transactions Derivative • Nov 17Chief Financial Officer notifies of intention to sell stockVineet Agarwal intends to sell 800 shares in the next 90 days after lodging an Intent To Sell Form on the 11th of November. If the sale is conducted around the recent share price of US$70.00, it would amount to US$56k. Since December 2023, Vineet has not owned shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold US$767k more than they bought, via options and on-market transactions in the last 12 months.공시 • Nov 05+ 1 more updateKorro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATDKorro Bio, Inc. announced a submission to the Bellberry HREC for a Phase 1/2 clinical study of KRRO-110 for AATD. A Clinical Advisory Board (CAB) comprised of distinguished lung and liver researchers and experts in AATD has also been assembled to help guide the clinical development strategy for KRRO-110. Subject to approval by the HREC and acceptance of the clinical trial notification (CTN) by Australia’s Therapeutic Goods Administration (TGA), Korro anticipates dosing the first participant in the Phase 1/2 study in the first quarter of 2025. An interim data readout for the Phase 1/2 study of KRRO-110 is anticipated in the second half of 2025, and completion of the study is expected in 2026.Recent Insider Transactions Derivative • Oct 20Chief Financial Officer notifies of intention to sell stockVineet Agarwal intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of October. If the sale is conducted around the recent share price of US$78.26, it would amount to US$800k. Since December 2023, Vineet has not owned shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold US$761k more than they bought, via options and on-market transactions in the last 12 months.공시 • Aug 28Korro Bio, Inc. Announces Board ChangesKorro Bio, Inc. announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage development to regulatory approval and commercialization. She most recently served as Chief Medical Officer at Agilent Technologies, where she established an industry-leading medical affairs organization and was responsible for integrating the voice of patients into business and clinical development strategy and decision-making. Previously, she was Chief Medical Officer and Head of Research and Development at Kaleido Biosciences. Before that, Dr. Knobil spent more than 20 years at GlaxoSmithKline (GSK) in roles of increasing responsibility, most recently serving as Chief Medical Officer. Dr. Knobil is currently a member of the Board of Directors at Nimbus Therapeutics, Marker Therapeutics and Pliant Therapeutics. Dr. Knobil is a recognized leader in the field, having authored numerous publications and presented at major industry conferences. She received an M.D. from the University of Texas Southwestern Medical School and completed her subsequent fellowship in Pulmonary Medicine and Critical Care Medicine at Johns Hopkins University.분석 기사 • Aug 15We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...Board Change • May 17High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. Director David Lucchino is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • May 16Korro Bio, Inc. Announces the Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerKorro Bio, Inc. announced the appointment of Dr. Kemi Olugemo as Chief Medical Officer. Dr. Olugemo brings more than 10 years of industry experience focused on clinical development and regulatory strategy. She joins Korro after serving as VP & Therapeutic Head, Neurology Global Clinical Development at Ultragenyx Pharmaceutical. In this role, she directed and oversaw the overall strategy for clinical drug product development, supported the development of global regulatory plans, and identified critical opportunities for external collaborations. Dr. Olugemo holds an M.D. from the University of Maryland School of Medicine and a B.Sc. in Clinical Laboratory Science from the University of Massachusetts, Lowell. With her experience in rare and more prevalent diseases, Dr. Olugemo will provide invaluable expertise and leadership to advance Korro’s clinical and regulatory initiatives.공시 • May 01Korro Bio, Inc., Annual General Meeting, Jun 11, 2024Korro Bio, Inc., Annual General Meeting, Jun 11, 2024, at 13:30 US Eastern Standard Time. Agenda: To consider Election of two Class II directors, Ali Behbahani and Timothy Pearson, nominated by board of directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders; to consider Approval of an amendment to Restated Certificate of Incorporation to limit the liability of certain officers as permitted by amendments to Delaware law; to consider Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider other matters.공시 • Apr 23Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.On April 22, 2024, Korro Bio, Inc. closed the transaction.공시 • Apr 19Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.Korro Bio, Inc. announces it has entered into a subscription agreement with a number of institutional accredited investors to issue 1,249,283 shares of common stock at a issue price of $56 per share for gross proceeds of $69,959,848 on April 17, 2024. The transaction will include participation from Deep Track Capital, as lead investor and Atlas Venture, Blue Owl Healthcare Opportunities, NEA, Rock Springs Capital, Tri Locum Partners, and other leading healthcare investors. The transaction is expected to close on April 22, 2024.분석 기사 • Mar 30We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Dec 08New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 8.4% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Significant insider selling over the past 3 months (US$84k sold).공시 • Dec 07Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin DeficiencyKorro Bio, Inc. has nominated its first development candidate, KRRO-110, for the potential treatment of AATD. KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using clinically validated LNP technology licensed from Genevant. KRRO-110 is designed to co-opt an endogenous enzyme Adenosine Deaminase Acting on RNA (ADAR) to repair a pathogenic single nucleotide variant (SNV) on RNA and restore production of normal A1AT. AATD is an inherited genetic disorder caused by SNVs in the SERPINA1 gene that can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and liver disease. There are an estimated 3.4 million individuals with deficiency allele combinations worldwide. The only current FDA-approved treatment for AATD is augmentation therapy, a once-weekly infusion of pooled human plasma-derived A1AT protein, which does not adequately address the manifestations of AATD.공시 • Nov 30Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance CommitteeKorro Bio, Inc. announced the appointment of Rachel Meyers, PhD, to the company’s board of directors. Dr. Meyers is a seasoned biotechnology veteran whose experience in life sciences spans over two decades. Most recently, Dr. Meyers served as Chief Scientific Officer of Faze Medicines. Previously, she was an Entrepreneur-in-Residence at Third Rock Ventures. Before that, Dr. Meyers held multiple leadership positions at Alnylam Pharmaceuticals for over 13 years, most recently as Senior Vice President of Research and RNAi Lead Development. Rachel completed her post-doctoral training at Harvard University and holds a PhD in Biology from the Massachusetts Institute of Technology and a BA in Biochemistry from Brandeis University. Dr. Meyers was also appointed by the Board upon the recommendation of the NCG Committee to serve as a member of the Nominating and Corporate Governance Committee or NCG Committee.Board Change • Nov 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Omar Khwaja was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Nov 07Frequency Therapeutics, Inc. announced that it has received $117.249989 million in funding from a group of investorsOn November 6, 2023, Frequency Therapeutics, Inc. closed the transaction. The company issued 42,176,255 common shares at a price of $2.78 per share for gross proceeds of $117.249989 million.이익 및 매출 성장 예측NasdaqCM:KRRO - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028N/A-113-73-66612/31/20270-91-63-57712/31/20261-79-66-5593/31/20264-113-71-70N/A12/31/20256-117-79-79N/A9/30/20257-88-70-68N/A6/30/20256-91-74-67N/A3/31/20255-87-75-63N/A12/31/20242-84-78-60N/A9/30/2024N/A-88-92-74N/A6/30/2024N/A-85-83-69N/A3/31/2024N/A-81-81-69N/A12/31/2023N/A-81-75-67N/A9/30/2023N/A-72-69-61N/A6/30/2023N/A-69-73-64N/A3/31/2023N/A-64-66-61N/A12/31/2022N/A-58-59-54N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: KRRO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: KRRO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: KRRO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: KRRO 의 수익(연간 61.7%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: KRRO 의 수익(연간 61.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: KRRO의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/18 13:31종가2026/05/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Korro Bio, Inc.는 13명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Steven SeedhouseCantor Fitzgerald & Co.Tu Cam NguyenCGS InternationalKeay NakaeChardan Capital Markets, LLC10명의 분석가 더 보기
Major Estimate Revision • May 14Consensus EPS estimates upgraded to US$5.27 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$6.75 to -US$5.27 per share. Revenue forecast unchanged from US$500.0k at last update. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$20.38 unchanged from last update. Share price fell 16% to US$11.20 over the past week.
Major Estimate Revision • Mar 19Consensus revenue estimates increase by 52,586%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$1.27m to US$667.4m. Forecast losses expected to reduce from -US$8.27 to -US$6.75 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$19.33 to US$20.00. Share price fell 3.8% to US$11.06 over the past week.
Price Target Changed • Feb 12Price target increased by 123% to US$19.33Up from US$8.67, the current price target is an average from 6 analysts. New target price is 64% above last closing price of US$11.76. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$9.05 next year compared to a net loss per share of US$9.37 last year.
Price Target Changed • Sep 10Price target decreased by 8.4% to US$92.33Down from US$101, the current price target is an average from 9 analysts. New target price is 156% above last closing price of US$36.12. Stock is down 7.0% over the past year. The company is forecast to post a net loss per share of US$10.14 next year compared to a net loss per share of US$9.37 last year.
Major Estimate Revision • Aug 19Consensus revenue estimates increase by 47%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$3.31m to US$4.85m. EPS estimate fell from -US$9.55 to -US$10.14 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$99.23. Share price rose 20% to US$19.14 over the past week.
Price Target Changed • May 16Price target decreased by 13% to US$102Down from US$117, the current price target is an average from 10 analysts. New target price is 574% above last closing price of US$15.11. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$9.55 next year compared to a net loss per share of US$9.37 last year.
Major Estimate Revision • May 14Consensus EPS estimates upgraded to US$5.27 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$6.75 to -US$5.27 per share. Revenue forecast unchanged from US$500.0k at last update. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$20.38 unchanged from last update. Share price fell 16% to US$11.20 over the past week.
Reported Earnings • May 07First quarter 2026 earnings released: US$1.69 loss per share (vs US$2.49 loss in 1Q 2025)First quarter 2026 results: US$1.69 loss per share (improved from US$2.49 loss in 1Q 2025). Net loss: US$19.6m (loss narrowed 16% from 1Q 2025). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.
공시 • Apr 17Korro Bio, Inc., Annual General Meeting, Jun 10, 2026Korro Bio, Inc., Annual General Meeting, Jun 10, 2026.
Major Estimate Revision • Mar 19Consensus revenue estimates increase by 52,586%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$1.27m to US$667.4m. Forecast losses expected to reduce from -US$8.27 to -US$6.75 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$19.33 to US$20.00. Share price fell 3.8% to US$11.06 over the past week.
New Risk • Mar 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 9.8% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$108m net loss in 3 years).
공시 • Mar 09Korro Bio, Inc. announced that it expects to receive $84.996839 million in funding from a group of investorsKorro Bio, Inc announced a private placement and entered into a subscription agreement to issue 4,501,928 common shares at price of $11.11 per share for aggregate proceeds of $50,016,420.08 and 3,148,836 pre-funded warrants at a price of $11.109 for aggregate proceeds of $34,980,419.124, total gross proceeds amounting to $84,996,839.204 on March 9. 2026. The transaction included participation from lead Investor Venrock Healthcare Capital Partners, ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, and New Enterprise Associates. The pre-funded warrants have an exercise price of $0.001 per underlying share of common stock, are immediately exercisable and have no expiration date. The transaction is expected to close on March 10, 2026 subject to customary closing conditions. The securities will be issued in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the 1933 Act and not in reliance upon any of the safe harbors set forth in Regulation D promulgated thereunder.
Price Target Changed • Feb 12Price target increased by 123% to US$19.33Up from US$8.67, the current price target is an average from 6 analysts. New target price is 64% above last closing price of US$11.76. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$9.05 next year compared to a net loss per share of US$9.37 last year.
Board Change • Feb 12High number of new and inexperienced directorsThere are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Independent Director Ali Behbahani is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Nov 13+ 2 more updatesKorro Bio, Inc. Provides Updates on KRRO-110 in Alpha-1 Antitrypsin DeficiencyKorro Bio, Inc. provided a program update for its Phase 1/2a REWRITE clinical trial of KRRO-110 in AATD. The REWRITE Phase 1/2a clinical trial is a two-part single and multiple-dose escalating study evaluating the safety and tolerability of KRRO-110, including healthy adults and clinically stable AATD patients with the PiZZ genotype. Korro has completed all six planned single ascending dose (SAD) healthy volunteer (HV) cohorts. Each HV cohort consisted of six participants, with four receiving active drug and two receiving placebo. Doses of KRRO-110 tested in the HVs (n=24) include 0.04, 0.1, 0.2, 0.4, 0.8 and 1.2 mg/kg, with the primary objective to evaluate safety and tolerability. KRRO-110 is currently being evaluated in two AATD patient cohorts at 0.6 mg/kg (n=3) and 0.8 mg/kg (n=4), with seven patients dosed. The AATD patient cohorts are open label with up to four patients in each cohort. There are currently no plans to complete additional SAD patient cohorts for KRRO-110. Korro is evaluating the totality of the clinical data to evaluate the next steps, if any, for KRRO-110 in the multiple-ascending dose (MAD) portion of the REWRITE clinical trial. KRRO-110 Safety Observations (as of the November 6, 2025 Data Cutoff Date): No dose-limiting toxicities or treatment emergent serious adverse events observed. Mild-to-moderate infusion-related reactions (IRRs) observed in two healthy volunteers at the highest dose of 1.2 mg/kg, two AATD patients at 0.6 mg/kg, and two AATD patients at 0.8 mg/kg. All IRRs resolved within 24 hours post KRRO-110 dosing; intervention was limited to antipyretics and antihistamines. KRRO-110 safety profile is consistent with Lipid Nanoparticles (LNP) infusion-related class effects. KRRO-110 Pharmacodynamic and Pharmacokinetic Observations (as of the November 6, 2025 Data Cutoff Date): Across five AATD patients in the two SAD cohorts evaluable with turbidimetry, the greatest peak total AAT protein was approximately 10 µM and the greatest increase of total AAT protein from baseline was approximately 3 µM. The total AAT protein levels following single-dose administration did not reach the protective threshold of 11 µM. In three of the AATD patients dosed with 0.8 mg/kg evaluable with LC/MS, functional M-AAT protein was observed in each of the patients following administration of KRRO-110. The greatest increase of M-AAT protein from baseline observed at any time point was approximately 2 µM. Functional M-AAT protein lasted up to four weeks for the first patient evaluable with LC/MS, consistent with durability of editing and endogenous M-AAT protein half-life. Pharmacokinetic differences in the components of KRRO-110 in plasma were observed between HV and AATD patients, with apparent faster disassociation of KRRO-110, suggesting variability of this formulation in AATD patients compared to HV following a single dose. No evidence of bystander editing observed to date, suggesting high specificity, based on LC/MS data on M-AAT and Z-AAT. KRRO-110 Regulatory Milestones Validate OPERA Platform Potential: First-ever RNA editing technology to receive Investigational New Drug clearance by the U.S. Food and Drug Administration (FDA) to Korro’s knowledge. Fast Track designation granted by the FDA. Orphan Drug Designation granted by both the FDA and European Medicines Agency.
분석 기사 • Oct 23Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Oct 08Korro Bio, Inc. Announces Chief Financial Officer Changes, Effective October 17, 2025On October 7, 2025, Vineet Agarwal announced his intention to resign from his position of Chief Financial Officer of Korro Bio, Inc., or Korro, effective October 17, 2025 to pursue another opportunity. In order to ensure the smooth transition of his functions, Mr. Agarwal has agreed to be available to serve as an advisor for 30 days thereafter. The board of directors of Korro, or the Board, and Korro are incredibly thankful to Mr. Agarwal for his long-standing service at Korro. In light of Mr. Agarwal’s resignation, the Board appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim Chief Financial Officer and principal financial officer, in addition to his current duties effective from October 17, 2025.
Price Target Changed • Sep 10Price target decreased by 8.4% to US$92.33Down from US$101, the current price target is an average from 9 analysts. New target price is 156% above last closing price of US$36.12. Stock is down 7.0% over the past year. The company is forecast to post a net loss per share of US$10.14 next year compared to a net loss per share of US$9.37 last year.
Major Estimate Revision • Aug 19Consensus revenue estimates increase by 47%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$3.31m to US$4.85m. EPS estimate fell from -US$9.55 to -US$10.14 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$99.23. Share price rose 20% to US$19.14 over the past week.
분석 기사 • Jul 05We're Keeping An Eye On Korro Bio's (NASDAQ:KRRO) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
공시 • Jun 30+ 5 more updatesKorro Bio, Inc.(NasdaqCM:KRRO) dropped from Russell 3000E Growth IndexKorro Bio, Inc.(NasdaqCM:KRRO) dropped from Russell 3000E Growth Index
New Risk • Jun 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 9.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years). Revenue is less than US$5m (US$4.8m revenue).
Price Target Changed • May 16Price target decreased by 13% to US$102Down from US$117, the current price target is an average from 10 analysts. New target price is 574% above last closing price of US$15.11. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$9.55 next year compared to a net loss per share of US$9.37 last year.
Major Estimate Revision • May 14Consensus revenue estimates increase by 137%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from US$1.35m to US$3.20m. Forecast losses expected to reduce from -US$10.23 to -US$9.51 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$117 to US$102. Share price was steady at US$14.11 over the past week.
공시 • Apr 30Korro Bio, Inc., Annual General Meeting, Jun 11, 2025Korro Bio, Inc., Annual General Meeting, Jun 11, 2025.
Price Target Changed • Apr 29Price target decreased by 7.3% to US$117Down from US$126, the current price target is an average from 10 analysts. New target price is 601% above last closing price of US$16.67. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$10.23 next year compared to a net loss per share of US$9.37 last year.
Major Estimate Revision • Apr 24Consensus revenue estimates increase by 156%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$250.0k to US$640.0k. EPS estimate unchanged from -US$10.40 at last update. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$139 to US$122. Share price rose 25% to US$17.44 over the past week.
Price Target Changed • Apr 17Price target decreased by 9.9% to US$126Down from US$140, the current price target is an average from 9 analysts. New target price is 807% above last closing price of US$13.90. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$10.40 next year compared to a net loss per share of US$9.37 last year.
공시 • Apr 01Korro Bio, Inc. Appoints Loïc Vincent as Chief Scientific OfficerKorro Bio, Inc. announced the appointment of Loïc Vincent as Chief Scientific Officer. Dr. Vincent joins Korro with more than 20 years in drug discovery and translational research across academia, biotech and the pharmaceutical industry. Throughout his career, Dr. Vincent led teams that advanced more than 20 drugs into clinical development based on various therapeutic modalities including small molecules, biologics, viral platforms and cell therapies. Prior to joining Korro, Dr. Vincent served as Chief Scientific Officer at Affini-T Therapeutics leading efforts to advance next-generation therapies. Previously, he was Head of the Oncology Drug Discovery Unit and Immunology Unit at Takeda. Before that, Dr. Vincent led Oncology Drug Discovery Pharmacology, Immunotherapy and Oncology External Innovation teams at Sanofi, and earlier in his career, he headed Pharmacology and Oncology programs at Endotis Pharma. Dr. Vincent currently serves on the Scientific Advisory Boards of bit.bio and General Inception, and is a Director on the Board of Alaya.bio. Dr. Vincent obtained his Ph.D. in pharmacology from the University of Rouen, France, and completed his postdoctoral fellowship in oncology at the Weill Medical College of Cornell University, New York.
분석 기사 • Mar 19Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although...
공시 • Feb 13Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting OfficerEffective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., is taking a temporary medical leave of absence. Accordingly, effective from February 11, 2025, Korro’s Board of Directors appointed Mr. Oliver Dolan, Senior Vice President, Finance, to serve as Korro’s interim principal accounting officer, in each case, in addition to their current duties. Mr. Dolan, age 42, has served as Korro’s Senior Vice President of Finance since January 2024. Prior to joining Korro, Mr. Dolan served as Vice President, Accounting, Tax and Treasury at Unity Biotechnology from December 2020 to December 2023. Prior to that, Mr. Dolan served as Head of Finance at Haven Healthcare from May 2020 to December 2020. Prior to that, Mr. Dolan served as Vice President of Finance at Compass Therapeutics from October 2018 to May 2020. Mr. Dolan holds an MBA from MIT Sloan School of Management, a Bachelor of Commerce degree from the University College Dublin and he is licensed as a Certified Public Accountant.
공시 • Jan 13Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin DeficiencyKorro Bio, Inc. announced the initiation of dosing in its REWRITE study investigating KRRO-110 as a potential treatment for individuals with Alpha-1 Antitrypsin Deficiency (AATD). REWRITE is a two-part single and multiple dose-escalating study that will evaluate the safety and tolerability of KRRO-110 in up to 64 participants, including healthy adults and clinically stable AATD patients with the PiZZ genotype. Secondary and exploratory endpoints include pharmacokinetic and pharmacodynamic parameters that will guide optimal dose selection for later stage studies. Interim data from Part 1 (single ascending doses in healthy volunteers and individuals with AATD) is expected in the second half of 2025, and completion of the study is anticipated in 2026. For additional information about the REWRITE study, visit ClinicalTrials.gov (NCT06677307). In addition to advancing KRRO-110, Korro is progressing a pipeline of wholly owned programs and a Novo Nordisk partnered program in a cardiometabolic indication towards the clinic.
공시 • Dec 03Korro Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Korro Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
분석 기사 • Nov 28We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Recent Insider Transactions Derivative • Nov 17Chief Financial Officer notifies of intention to sell stockVineet Agarwal intends to sell 800 shares in the next 90 days after lodging an Intent To Sell Form on the 11th of November. If the sale is conducted around the recent share price of US$70.00, it would amount to US$56k. Since December 2023, Vineet has not owned shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold US$767k more than they bought, via options and on-market transactions in the last 12 months.
공시 • Nov 05+ 1 more updateKorro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATDKorro Bio, Inc. announced a submission to the Bellberry HREC for a Phase 1/2 clinical study of KRRO-110 for AATD. A Clinical Advisory Board (CAB) comprised of distinguished lung and liver researchers and experts in AATD has also been assembled to help guide the clinical development strategy for KRRO-110. Subject to approval by the HREC and acceptance of the clinical trial notification (CTN) by Australia’s Therapeutic Goods Administration (TGA), Korro anticipates dosing the first participant in the Phase 1/2 study in the first quarter of 2025. An interim data readout for the Phase 1/2 study of KRRO-110 is anticipated in the second half of 2025, and completion of the study is expected in 2026.
Recent Insider Transactions Derivative • Oct 20Chief Financial Officer notifies of intention to sell stockVineet Agarwal intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of October. If the sale is conducted around the recent share price of US$78.26, it would amount to US$800k. Since December 2023, Vineet has not owned shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold US$761k more than they bought, via options and on-market transactions in the last 12 months.
공시 • Aug 28Korro Bio, Inc. Announces Board ChangesKorro Bio, Inc. announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage development to regulatory approval and commercialization. She most recently served as Chief Medical Officer at Agilent Technologies, where she established an industry-leading medical affairs organization and was responsible for integrating the voice of patients into business and clinical development strategy and decision-making. Previously, she was Chief Medical Officer and Head of Research and Development at Kaleido Biosciences. Before that, Dr. Knobil spent more than 20 years at GlaxoSmithKline (GSK) in roles of increasing responsibility, most recently serving as Chief Medical Officer. Dr. Knobil is currently a member of the Board of Directors at Nimbus Therapeutics, Marker Therapeutics and Pliant Therapeutics. Dr. Knobil is a recognized leader in the field, having authored numerous publications and presented at major industry conferences. She received an M.D. from the University of Texas Southwestern Medical School and completed her subsequent fellowship in Pulmonary Medicine and Critical Care Medicine at Johns Hopkins University.
분석 기사 • Aug 15We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Board Change • May 17High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. Director David Lucchino is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • May 16Korro Bio, Inc. Announces the Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerKorro Bio, Inc. announced the appointment of Dr. Kemi Olugemo as Chief Medical Officer. Dr. Olugemo brings more than 10 years of industry experience focused on clinical development and regulatory strategy. She joins Korro after serving as VP & Therapeutic Head, Neurology Global Clinical Development at Ultragenyx Pharmaceutical. In this role, she directed and oversaw the overall strategy for clinical drug product development, supported the development of global regulatory plans, and identified critical opportunities for external collaborations. Dr. Olugemo holds an M.D. from the University of Maryland School of Medicine and a B.Sc. in Clinical Laboratory Science from the University of Massachusetts, Lowell. With her experience in rare and more prevalent diseases, Dr. Olugemo will provide invaluable expertise and leadership to advance Korro’s clinical and regulatory initiatives.
공시 • May 01Korro Bio, Inc., Annual General Meeting, Jun 11, 2024Korro Bio, Inc., Annual General Meeting, Jun 11, 2024, at 13:30 US Eastern Standard Time. Agenda: To consider Election of two Class II directors, Ali Behbahani and Timothy Pearson, nominated by board of directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders; to consider Approval of an amendment to Restated Certificate of Incorporation to limit the liability of certain officers as permitted by amendments to Delaware law; to consider Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider other matters.
공시 • Apr 23Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.On April 22, 2024, Korro Bio, Inc. closed the transaction.
공시 • Apr 19Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.Korro Bio, Inc. announces it has entered into a subscription agreement with a number of institutional accredited investors to issue 1,249,283 shares of common stock at a issue price of $56 per share for gross proceeds of $69,959,848 on April 17, 2024. The transaction will include participation from Deep Track Capital, as lead investor and Atlas Venture, Blue Owl Healthcare Opportunities, NEA, Rock Springs Capital, Tri Locum Partners, and other leading healthcare investors. The transaction is expected to close on April 22, 2024.
분석 기사 • Mar 30We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Dec 08New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 8.4% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Significant insider selling over the past 3 months (US$84k sold).
공시 • Dec 07Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin DeficiencyKorro Bio, Inc. has nominated its first development candidate, KRRO-110, for the potential treatment of AATD. KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using clinically validated LNP technology licensed from Genevant. KRRO-110 is designed to co-opt an endogenous enzyme Adenosine Deaminase Acting on RNA (ADAR) to repair a pathogenic single nucleotide variant (SNV) on RNA and restore production of normal A1AT. AATD is an inherited genetic disorder caused by SNVs in the SERPINA1 gene that can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and liver disease. There are an estimated 3.4 million individuals with deficiency allele combinations worldwide. The only current FDA-approved treatment for AATD is augmentation therapy, a once-weekly infusion of pooled human plasma-derived A1AT protein, which does not adequately address the manifestations of AATD.
공시 • Nov 30Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance CommitteeKorro Bio, Inc. announced the appointment of Rachel Meyers, PhD, to the company’s board of directors. Dr. Meyers is a seasoned biotechnology veteran whose experience in life sciences spans over two decades. Most recently, Dr. Meyers served as Chief Scientific Officer of Faze Medicines. Previously, she was an Entrepreneur-in-Residence at Third Rock Ventures. Before that, Dr. Meyers held multiple leadership positions at Alnylam Pharmaceuticals for over 13 years, most recently as Senior Vice President of Research and RNAi Lead Development. Rachel completed her post-doctoral training at Harvard University and holds a PhD in Biology from the Massachusetts Institute of Technology and a BA in Biochemistry from Brandeis University. Dr. Meyers was also appointed by the Board upon the recommendation of the NCG Committee to serve as a member of the Nominating and Corporate Governance Committee or NCG Committee.
Board Change • Nov 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Omar Khwaja was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Nov 07Frequency Therapeutics, Inc. announced that it has received $117.249989 million in funding from a group of investorsOn November 6, 2023, Frequency Therapeutics, Inc. closed the transaction. The company issued 42,176,255 common shares at a price of $2.78 per share for gross proceeds of $117.249989 million.